These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 21566092

  • 1. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
    Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M.
    Blood; 2011 Jul 14; 118(2):276-81. PubMed ID: 21566092
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S.
    Cancer; 2006 Jun 15; 106(12):2645-51. PubMed ID: 16688777
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment.
    Owen RG, Hillmen P, Rawstron AC.
    Clin Lymphoma; 2005 Mar 15; 5(4):278-81. PubMed ID: 15794865
    [Abstract] [Full Text] [Related]

  • 6. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
    Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA.
    Leuk Lymphoma; 2009 Oct 15; 50(10):1589-96. PubMed ID: 19863336
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A.
    Blood; 2002 Aug 01; 100(3):768-73. PubMed ID: 12130484
    [Abstract] [Full Text] [Related]

  • 8. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T.
    BioDrugs; 2005 Aug 01; 19(1):9-22. PubMed ID: 15691213
    [Abstract] [Full Text] [Related]

  • 9. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C, Patton D, Gordon LI, Riley MB, Kuzel T, Tallman MS, Rosen ST.
    Leuk Lymphoma; 2004 Nov 01; 45(11):2269-73. PubMed ID: 15512816
    [Abstract] [Full Text] [Related]

  • 10. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
    Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S.
    Blood; 2010 Oct 21; 116(16):3080-8. PubMed ID: 20587785
    [Abstract] [Full Text] [Related]

  • 11. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
    Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M.
    Cancer; 2004 Sep 01; 101(5):999-1008. PubMed ID: 15329909
    [Abstract] [Full Text] [Related]

  • 12. Alemtuzumab in B-cell chronic lymphocytic leukemia.
    Shapira I, Grossbard ML.
    Clin Lymphoma; 2004 Mar 01; 4(4):228-9. PubMed ID: 15072614
    [No Abstract] [Full Text] [Related]

  • 13. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
    Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM.
    Leuk Lymphoma; 2009 Dec 01; 50(12):1969-76. PubMed ID: 19860617
    [Abstract] [Full Text] [Related]

  • 14. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
    Zhu WM, Li Y, Yu C, Li N, Li JS.
    Inflamm Bowel Dis; 2011 Jul 01; 17(7):E72-3. PubMed ID: 21538714
    [No Abstract] [Full Text] [Related]

  • 15. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K, Wilson WH.
    Leuk Lymphoma; 2010 Sep 01; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract] [Full Text] [Related]

  • 16. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
    O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ.
    Cancer; 2003 Dec 15; 98(12):2657-63. PubMed ID: 14669286
    [Abstract] [Full Text] [Related]

  • 17. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
    Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ.
    Blood; 2003 May 01; 101(9):3413-5. PubMed ID: 12522009
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M, Bacher K, Thierens H, Slegers G, Dierckx RA, De Vos F.
    Nucl Med Biol; 2008 Jul 01; 35(5):599-604. PubMed ID: 18589304
    [Abstract] [Full Text] [Related]

  • 19. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
    Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS.
    Leuk Lymphoma; 2001 Mar 01; 41(1-2):77-87. PubMed ID: 11342359
    [Abstract] [Full Text] [Related]

  • 20. Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
    Ishizawa K, Fukuhara N, Nakaseko C, Chiba S, Ogura M, Okamoto A, Sunaga Y, Tobinai K.
    Jpn J Clin Oncol; 2017 Jan 01; 47(1):54-60. PubMed ID: 28122892
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.